CUPERTINO, Calif. , Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET® line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branf...
DURECT Corporation (NASDAQ:DRRX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jim Brown - Co-Founder, Chief Executive Officer, President, Director Tim Papp - Chief Financial Officer WeiQi Lin - Executive Vice President of Research and Development, Principal Scientist Conference Call Participants Thomas Yip - H.C. Wainwright Karl Burns - Northland Capital M...
- Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif.
CUPERTINO, Calif. , Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024.
CUPERTINO, Calif. , Oct. 17, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024, organized by the America...
- Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of l...
CUPERTINO, Calif. , Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C.
DURECT Corporation (NASDAQ:DRRX ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Tim Papp - CFO & Secretary Jim Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer Ed Arce - H.C. Wainwright Carl Byrnes - Northland Capital Markets Operator Ladie...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.